ACT Style Guidelines
ACT Style Guidelines
When ever possible is it best to design pages for ACTMagazine.com using as much HTML styled text as possible. This page provides guidance on designing content for the primary (center) column. Below you will also find examples of HTML styled text as it will appear in the primary column of ACTmagazine.com.
Content for the primary column should be designed to fit a maximun column width of 620 pixels.
The color palette for ACTMagazine.com is as follows:
red color: #8E0006 RED COLOR span class="red"
red link hover color: #B8000F RED COLOR
dark gray color: #333 DARK GRAY span class="darkgray"
light gray color: #333 LIGHT GRAY span class="lightgray"
yellow color: #FFFFCC YELLOW span class="yellow"
HTML styling on ACTMagazine.com:
[h1] Nun iz urino sekse subjunkcio.
[h2] On eko alio familiano alternativdemando.
[h3] Bis ci centilitro subtegmentejo, plue lasi afro troa al.
[h4] Via os ajna ceceo.
[h5] Pro plus frato grado sh, nv ador praanta.
[P] Tri tc grupo triliono la?longe, ig tiea seksa ies. Er ism okej multa ablativa, u a? peta kvanta. Veo peti ikso ol, ien danki tamen et. Ebl oj brosi pentekosto profitanto. Be mil dato maksimume, o peta estro nen. Ree si titolo kapabl vortludo. Adjektiva dikfingro kunmeta?o ik sia, armo s'joro log in. Veka krome lanta via ac. Nk elen hoketo nominativa cis, mal samo sekso dekuma da, so devi komplika int. To pro samo e?o kernovorto, far spite kasedo ekkria ut. Super turpa emfazado jen as, hago lasta iufoje io tet. Mono onjo gardi ha sia, poa centi refleksiva ut. Ia deci usono anta?eniri cit, pri alial proto frakcistreko am. Altlernejo prirespondi unu nf, iam unuj da?rigi ig. Dum rilata dekuma ut, emfazo kazablanko beda?rinde ing id, geto minimume centimetro muo um. Mal jo apud konsonanto, sur kapabl dekuma okulvitroj if. Bisi ikso sanskrito men if, hago ologi la nea. Unt ie iama pluso. To poa estro priskribo, sed bv finnlando multiplikite, vendo kvanta postesigno tio re. Cia ju proto minca, at iam na? haltostreko demandovorto. Oj mini jesa makro hot. Piko pago ekstera?o far fo, sat giga bat'o priskribo gh, ge ebl sude.
[link style in P tag] Be mil dato maksimume o peta estro nen. Ree si titolo kapabl vortludo.
[link style in h1] Nun iz urino sekse subjunkcio.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
